Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes

Antiviral Research

Volumn 88, Issue 2, 2010, Pages 129-142

  Bray, Mike ^a   Di Mascio, Michele ^a   de Kok Mercado, Fabian ^a   Mollura, Daniel J ^b   Jagoda, Elaine ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiviral therapy; Infectious disease imaging; Positron emission tomography; Radiopharmaceuticals; Single photon emission computed tomography

Indexed keywords

2' FLUORO 2' DEOXY 1 B DEXTRO BETA ARABINOFURANOSYL 5 ETHYLURACIL F 18; 2' FLUORO 2' DEOXY 1 BETA DEXTRO BETA ARABINOFURANOSYL 5 ETHYLURACIL F 18; 2' FLUORO 5 METHYL 1 BETA DEXTRO ARABINOSYLURACIL C 14; 3' FLUOROTHYMIDINE F 18; 9 (3 FLUORO 2 PHOSPHONOMETHOXYPROPYL)ADENINE F 18; BISMUTH; BROMINE 76; CARBON 11; CLEVUDINE C 11; COPPER 64; E 5 (2 IODOVINYL) 2' DEOXYURIDINE I 125; E 5 (2 IODOVINYL) 2' DEOXYURIDINE I 131; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; GALLIUM 68; INDIUM 111; IODINE 123; IODINE 124; META IODOBENZYLGUANIDINE I 124; NITROGEN 13; OXYGEN 18; PENTETREOTIDE INDIUM 111; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TENOFOVIR F 18; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANAMIVIR; ZIRCONIUM 89;

ANTIVIRAL THERAPY; ARENAVIRUS; AUTORADIOGRAPHY; BURKITT LYMPHOMA; CELL SURFACE; CHELATION; CORONAVIRUS; CYTOMEGALOVIRUS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RETENTION; DRUG TISSUE LEVEL; DRUG UPTAKE; FLAVIVIRUS; GENE DUPLICATION; GLUCOSE METABOLISM; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA A (H1N1); LIVER TOXICITY; MEMBRANE FUSION; METHYLATION; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; ORTHOMYXOVIRUS; PARAMYXOVIRUS; PICORNAVIRUS; POSITRON EMISSION TOMOGRAPHY; POXVIRUS; PRIORITY JOURNAL; RETROVIRUS; REVIEW; SCINTILLATION CAMERA; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTITUTION REACTION; VIRUS ASSEMBLY; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS GENE; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BINDING SITES; EPITOPES; HUMANS; MOLECULAR PROBES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIONUCLIDE IMAGING; THYMIDINE; THYMIDINE KINASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VIRAL STRUCTURAL PROTEINS; VIRION; VIRUS DISEASES; VIRUS REPLICATION; VIRUSES;

ANIMALIA; HEPATITIS C VIRUS; SIMPLEXVIRUS;

EID: 77958153808     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.08.005     Document Type: Review

References (104)

1. Alauddin M.M., Conti P.S., Mazza S.M., Hamzeh F.M., Lever J.R. 9-[(3-[18F]-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG): a potential imaging agent of viral infection and gene therapy using PET. Nucl. Med. Biol. 1996, 23:787-792.
2. Beigel J., Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008, 78:91-102.
3. Bellani G., Guerra L., Pesenti A., Messa C. Imaging of lung inflammation during severe influenza A: H1N1. Intensive Care Med. 2010, 36:717-718.
4. Bellani G., Messa C., Guerra L., Spagnolli E., Foti G., Patroniti N., Fumagalli R., Musch G., Fazio F., Pesenti A. Lungs of patients with acute respiratory distress syndrome show diffuse inflammation in normally aerated regions: a [18F]-fluoro-2-deoxy-D-glucose PET/CT study. Crit. Care Med. 2009, 37:2216-2222.
5. Bennett J.J., Tjuvajev J., Johnson P., Doubrovin M., Akhurst T., Malholtra S., Hackman T., Balatoni J., Finn R., Larson S.M., Federoff H., Blasberg R., Fong Y. Positron emission tomography imaging for herpes virus infection: implications for oncolytic viral treatments of cancer. Nat. Med. 2001, 7:859-863.
6. Bergstrom M., Cass L.M., Valind S., Westerberg G., Lundberg E.L., Gray S., Bye A., Langstrom B. Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography. Clin. Pharmacokinet. 1999, 36(Suppl. 1):33-39.
7. Bettegowda C., Foss C.A., Cheong I., Wang Y., Diaz L., Agrawal N., Fox J., Dick J., Dang L.H., Zhou S., Kinzler K.W., Vogelstein B., Pomper M.G. Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil. Proc. Natl. Acad. Sci. USA 2005, 102:1145-1150.
8. Bolken T.C., Laquerre S., Zhang Y., Bailey T.R., Pevear D.C., Kickner S.S., Sperzel L.E., Jones K.F., Warren T.K., Amanda Lund S., Kirkwood-Watts D.L., King D.S., Shurtleff A.C., Guttieri M.C., Deng Y., Bleam M., Hruby D.E. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 2006, 69:86-97.
9. Brader P., Kelly K., Gang S., Shah J.P., Wong R.J., Hricak H., Blasberg R.G., Fong Y., Gil Z. Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET. PLoS One 2009, 4:e4789.
10. Brunetti A., Berg G., Di Chiro G., Cohen R.M., Yarchoan R., Pizzo P.A., Broder S., Eddy J., Fulham M.J., Finn R.D., et al. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study. J. Nucl. Med. 1989, 30:581-590.
11. Brust D., Polis M., Davey R., Hahn B., Bacharach S., Whatley M., Fauci A.S., Carrasquillo J.A. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 2006, 20:985-993.
12. Buscombe J.R., Oyen W.J., Grant A., Claessens R.A., van der Meer J., Corstens F.H., Ell P.J., Miller R.F. Indium-111-labeled polyclonal human immunoglobulin: identifying focal infection in patients positive for human immunodeficiency virus. J. Nucl. Med. 1993, 34:1621-1625.
13. Buursma A.R., de Vries E.F., Garssen J., Kegler D., van Waarde A., Schirm J., Hospers G.A., Mulder N.H., Vaalburg W., Klein H.C. [18F]FHPG positron emission tomography for detection of herpes simplex virus (HSV) in experimental HSV encephalitis. J. Virol. 2005, 79:7721-7727.
14. Cagnin A., Kassiou M., Meikle S.R., Banati R.B. Positron emission tomography imaging of neuroinflammation. Neurotherapeutics 2007, 4:443-452.
15. Casadevall A., Goldstein H., Dadachova E. Targeting host cells harbouring viruses with radiolabeled antibodies. Expert Opin. Biol. Ther. 2007, 7:595-597.
16. Cass L.M., Brown J., Pickford M., Fayinka S., Newman S.P., Johansson C.J., Bye A. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin. Pharmacokinet. 1999, 36(Suppl. 1):21-31.
17. Chakrabarti B.K., Maitra R.K., Ma X.Z., Kestler H.W. A candidate live inactivatable attenuated vaccine for AIDS. Proc. Natl. Acad. Sci. USA 1996, 93:9810-9815.
18. Chapman J., Abbott E., Alber D.G., Baxter R.C., Bithell S.K., Henderson E.A., Carter M.C., Chambers P., Chubb A., Cockerill G.S., Collins P.L., Dowdell V.C., Keegan S.J., Kelsey R.D., Lockyer M.J., Luongo C., Najarro P., Pickles R.J., Simmonds M., Taylor D., Tyms S., Wilson L.J., Powell K.L. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 2007, 51:3346-3353.
19. Chen D.L., Rosenbluth D.B., Mintun M.A., Schuster D.P. FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J. Appl. Physiol. 2006, 100:1602-1609.
20. Chen D.L., Schuster D.P. Positron emission tomography with [18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 286:L834-L840.
21. Chen F., Hu Y., Li D., Chen H., Zhang X.L. CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS One 2009, 4:e8142.
22. Chen N., Zhang Q., Yu Y.A., Stritzker J., Brader P., Schirbel A., Samnick S., Serganova I., Blasberg R., Fong Y., Szalay A.A. A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. Mol. Med. 2009, 15:144-151.
23. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
24. Cleator G.M., Klapper P.E., Lewis A.G., Sharma H.L., Longson M. Specific neuro-radiological diagnosis of herpes encephalitis in an animal model. Arch. Virol. 1988, 101:1-12.
25. Dadachova E., Patel M.C., Toussi S., Apostolidis C., Morgenstern A., Brechbiel M.W., Gorny M.K., Zolla-Pazner S., Casadevall A., Goldstein H. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med. 2006, 3:e427.
26. Davis S.L., Be N.A., Lamichhane G., Nimmagadda S., Pomper M.G., Bishai W.R., Jain S.K. Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One 2009, 4:e6297.
27. De Palma A.M., Vliegen I., De Clercq E., Neyts J. Selective inhibitors of picornavirus replication. Med. Res. Rev. 2008, 28:823-884.
28. de Vries E.F., van Waarde A., Harmsen M.C., Mulder N.H., Vaalburg W., Hospers G.A. [(11)C]FMAU and [(18)F]FHPG as PET tracers for herpes simplex virus thymidine kinase enzyme activity and human cytomegalovirus infections. Nucl. Med. Biol. 2000, 27:113-119.
29. De Winter F., Vogelaers D., Gemmel F., Dierckx R.A. Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21:247-257.
30. DeBlasi A., O'Reilly K., Motulsky H.J. Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol. Sci. 1989, 10:227-229.
31. Deville-Bonne D., El Amri C., Meyer P., Chen Y., Agrofoglio L.A., Janin J. Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties. Antiviral Res. 2010, 86:101-120.
32. Di Mascio M., Paik C.H., Carrasquillo J.A., Maeng J.S., Jang B.S., Shin I.S., Srinivasula S., Byrum R., Neria A., Kopp W., Catalfamo M., Nishimura Y., Reimann K., Martin M., Lane H.C. Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates. Blood 2009, 114:328-337.
33. Di Mascio M., Srinivasula S., Bhattacharjee A., Cheng L., Martiniova L., Herscovitch P., Lertora J., Kiesewetter D. Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography. Antimicrob. Agents Chemother. 2009, 53:4086-4095.
34. Diaz L.A., Foss C.A., Thornton K., Nimmagadda S., Endres C.J., Uzuner O., Seyler T.M., Ulrich S.D., Conway J., Bettegowda C., Agrawal N., Cheong I., Zhang X., Ladenson P.W., Vogelstein B.N., Mont M.A., Zhou S., Kinzler K.W., Vogelstein B., Pomper M.G. Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. PLoS ONE 2007, 2:e1007.
35. Dingli D., Peng K.W., Harvey M.E., Greipp P.R., O'Connor M.K., Cattaneo R., Morris J.C., Russell S.J. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004, 103:1641-1646.
36. Dong H., Zhang B., Shi P.Y. Flavivirus methyltransferase: a novel antiviral target. Antiviral Res. 2008, 80:1-10.
37. Douglas J.L., Panis M.L., Ho E., Lin K.Y., Krawczyk S.H., Grant D.M., Cai R., Swaminathan S., Chen X., Cihlar T. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob. Agents Chemother. 2005, 49:2460-2466.
38. Drummer H.E., Maerz A., Poumbourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett. 2003, 546:385-390.
39. Duraffour S., Vigne S., Vermeire K., Garcel A., Vanstreels E., Daelemans D., Yang G., Jordan R., Hruby D.E., Crance J.M., Garin D., Andrei G., Snoeck R. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently. Antivir. Ther. 2008, 13:977-990.
40. Ebihara H., Theriault S., Neumann G., Alimonti J.B., Geisbert J.B., Hensley L.E., Groseth A., Jones S.M., Geisbert T.W., Kawaoka Y., Feldmann H. In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J. Infect. Dis. 2007, 196(Suppl. 2):S313-S322.
41. Eckelman W.C. The application of receptor theory to receptor-binding and enzyme-binding oncologic radiopharmaceuticals. Nucl. Med. Biol. 1994, 21:759-769.
42. Eckelman W.C., Frank J.A., Brechbiel M. Theory and practice of imaging saturable binding sites. Invest. Radiol. 2002, 37:101-106.
43. Eckelman W.C., Reba R.C., Gibson R.E., Rzeszotarski W.J., Vieras F., Mazaitis J.K., Francis B. Receptor-binding radiotracers: a class of potential radiopharmaceuticals. J. Nucl. Med. 1979, 20:350-357.
44. Eckelman W.C., Reba R.C., Kelloff G.J. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov. Today 2008, 13:748-759.
45. Elion G.B. The biochemistry and mechanism of action of acyclovir. J. Antimicrob. Chemother. 1983, 12(Suppl. B):9-17.
46. Eriksson S., Munch-Petersen B., Johansson K., Eklund H. Structure and function of cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 2002, 59:1327-1346.
47. Frey, K.A., Albin, R.L., 2001. Receptor binding techniques. Curr. Protoc. Neurosci. Chapter 1, Unit 1-4.
48. Fu D.X., Tanhehco Y.C., Chen J., Foss C.A., Fox J.J., Lemas V., Chong J.M., Ambinder R.F., Pomper M.G. Virus-associated tumor imaging by induction of viral gene expression. Clin. Cancer Res. 2007, 13:1453-1458.
49. Gentry G.A. Viral thymidine kinases and their relatives. Pharmacol. Ther. 1992, 54:319-355.
50. Georgescu G., Chemaly R.F. Palivizumab: where to from here?. Expert Opin. Biol. Ther. 2009, 9:139-147.
51. Ghosh A.K., Gong G., Grum-Tokars V., Mulhearn D.C., Baker S.C., Coughlin M., Prabhakar B.S., Sleeman K., Johnson M.E., Mesecar A.D. Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:5684-5688.
52. Gill M.J., Samuel J., Wiebe L.I., Knaus E.E., Tyrrell D.L. Quantitative uptake studies of 131I-labeled (E)-5-(2-iodovinyl)-2'-deoxyuridine in herpes simplex virus-infected cells in vitro. Antimicrob. Agents Chemother. 1984, 25:476-478.
53. Goel A., Carlson S.K., Classic K.L., Greiner S., Naik S., Power A.T., Bell J.C., Russell S.J. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007, 110:2342-2350.
54. Green L.A., Nguyen K., Berenji B., Iyer M., Bauer E., Barrio J.R., Namavari M., Satyamurthy N., Gambhir S.S. A tracer kinetic model for 18F-FHBG for quantitating herpes simplex virus type 1 thymidine kinase reporter gene expression in living animals using PET. J. Nucl. Med. 2004, 45:1560-1570.
55. Hamed I.A., Wenzl J.E., Leonard J.C., Altshuler G.P., Pederson J.A. Pulmonary cytomegalovirus infection: detection by Gallium 67 imaging in the transplant patient. Arch. Intern. Med. 1979, 139:286-288.
56. Harty R.N. No exit: targeting the budding process to inhibit filovirus replication. Antiviral Res. 2009, 81:189-197.
57. Hatori A., Arai T., Yanamoto K., Yamasaki T., Kawamura K., Yui J., Konno F., Nakao R., Suzuki K., Zhang M.R. Biodistribution and metabolism of the anti-influenza drug [11C]oseltamivir and its active metabolite [11C]Ro 64-0802 in mice. Nucl. Med. Biol. 2009, 36:47-55.
58. Hevesy G., Paneth F. A Manual of Radioactivity 1938, Oxford University Press. 2nd ed.
59. Jacobs A., Tjuvajev J.G., Dubrovin M., Akhurst T., Balatoni J., Beattie B., Joshi R., Finn R., Larson S.M., Herrlinger U., Pechan P.A., Chiocca E.A., Breakefield X.O., Blasberg R.G. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res. 2001, 61:2983-2995.
60. Jagoda E.M., Vaquero J.J., Seidel J., Green M.V., Eckelman W.C. Experiment assessment of mass effects in the rat: implications for small animal PET imaging. Nucl. Med. Biol. 2004, 31:771-779.
61. Jeffries W.B., Waugh D., Abel P.W. Analysis of data from "cold saturation" radioligand binding experiments. Methods Mol. Biol. 1997, 73:331-342.
62. Katzenellenbogen J.A., Carlson K.E., Heiman D.F., Goswami R. Receptor-binding radiopharmaceuticals for imaging breast tumors: estrogen-receptor interactions and selectivity of tissue uptake of halogenated estrogen analogs. J. Nucl. Med. 1980, 21:550-558.
63. Klapper P.E., Cleator G.M., Bruce J.M., Longson M. Penetration of the blood-brain barrier by the antiviral drug (E)-5-(2-iodovinyl)-2'-deoxyuridine in a rat model of herpes encephalitis. Drug Des. Deliv. 1988, 3:57-67.
64. Konno F., Arai T., Zhang M.R., Hatori A., Yanamoto K., Ogawa M., Ito G., Odawara C., Yamasaki T., Kato K., Suzuki K. Radiosyntheses of two positron emission tomography probes: [11C]Oseltamivir and its active metabolite [11C]Ro 64-0802. Bioorg. Med. Chem. Lett. 2008, 18:1260-1263.
65. Kumar R., Basu S., Torigian D., Anand V., Zhuang H., Alavi A. Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin. Microbiol. Rev. 2008, 21:209-224.
66. Kumar V. Radiolabeled white blood cells and direct targeting of micro-organisms for infection imaging. Q. J. Nucl. Med. Mol. Imaging 2005, 49:325-338.
67. Kuruppu D., Brownell A.L., Zhu A., Yu M., Wang X., Kulu Y., Fuchs B.C., Kawasaki H., Tanabe K.K. Positron emission tomography of herpes simplex virus 1 oncolysis. Cancer Res. 2007, 67:3295-3300.
68. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bos M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A.M., Goudreau N., Kawai S.H., Kukolj G., Lagace L., LaPlante S.R., Narjes H., Poupart M.A., Rancourt J., Sentjens R.E., St George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Weldon S.M., Yong C.L., Llinas-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
69. Langen P., Etzold G., Hintsche R., Kowollik G. 3'-Deoxy-3'-fluorothymidine, a new selective inhibitor of DNA-synthesis. Acta Biol. Med. Ger. 1969, 23:759-766.
70. Larson R.A., Dai D., Hosack V.T., Tan Y., Bolken T.C., Hruby D.E., Amberg S.M. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 2008, 82:10768-10775.
71. Lefebvre E., Schiffer C.A. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 2008, 10:131-142.
72. Lescar J., Luo D., Xu T., Sampath A., Lim S.P., Canard B., Vasudevan S.G. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target. Antiviral Res. 2008, 80:94-101.
73. Leyssen P., De Clercq E., Neyts J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 2008, 78:9-25.
74. Livni E., Berker M., Hillier S., Waller S.C., Ogan M.D., Discordia R.P., Rienhart J.K., Rubin R.H., Fischman A.J. Preparation and pharmacokinetics of 11C labeled stavudine (d4T). Nucl. Med. Biol. 2004, 31:613-621.
75. Lomholt S. Pharmacology of bismuth, with reference to its employment in the therapy of syphilis. Br. J. Vener. Dis. 1925, 1:50-57.
76. Love C., Tomas M.B., Tronco G.G., Palestro C.J. FDG PET of infection and inflammation. Radiographics 2005, 25:1357-1368.
77. Mackie G.C. F-18 fluorodeoxyglucose positron emission tomographic imaging of cytomegalovirus pneumonia. Clin. Nucl. Med. 2004, 29:569-571.
78. McCart J.A., Mehta N., Scollard D., Reilly R.M., Carrasquillo J.A., Tang N., Deng H., Miller M., Xu H., Libutti S.K., Alexander H.R., Bartlett D.L. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol. Ther. 2004, 10:553-561.
79. McKinlay M.A., Steinberg B.A. Oral efficacy of WIN 51711 in mice infected with human poliovirus. Antimicrob. Agents Chemother. 1986, 29:30-32.
80. Miyagawa T., Gogiberidze G., Serganova I., Cai S., Balatoni J.A., Thaler H.T., Ageyeva L., Pillarsetty N., Finn R.D., Blasberg R.G. Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes. J. Nucl. Med. 2008, 49:637-648.
81. Nattermann J., Schneiders A.M., Leifeld L., Langhans B., Schulz M., Inchauspe G., Matz B., Brackmann H.H., Houghton M., Sauerbruch T., Spengler U. Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). J. Hepatol. 2005, 42:499-504.
82. Paeshuyse J., Letellier C., Froeyen M., Dutartre H., Vrancken R., Canard B., De Clercq E., Gueiffier A., Teulade J.C., Herdewijn P., Puerstinger G., Koenen F., Kerkhofs P., Baraldi P.G., Neyts J. A pyrazolotriazolopyrimidinamine inhibitor of bovine viral diarrhea virus replication that targets the viral RNA-dependent RNA polymerase. Antiviral Res. 2009, 82:141-147.
83. Patel S., Gibson R. In vivo site-directed radiotracers: a mini-review. Nucl. Med. Biol. 2008, 35:805-815.
84. Pauwels E.K., Sturm E.J., Bombardieri E., Cleton F.J., Stokkel M.P. Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J. Cancer Res. Clin. Oncol. 2000, 126:549-559.
85. Phelps M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. USA 2000, 97:9226-9233.
86. Porotto M., Carta P., Deng Y., Kellogg G.E., Whitt M., Lu M., Mungall B.A., Moscona A. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. J. Virol. 2007, 81:10567-10574.
87. Price R.W., Saito Y., Fox J.J. Prospects for the use of radiolabeled antiviral drugs in the diagnosis of herpes simplex encephalitis. Biochem. Pharmacol. 1983, 32:2455-2461.
88. Prichard M.N. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol. 2009, 19:215-229.
89. Prichard M.N., Keith K.A., Johnson M.P., Harden E.A., McBrayer A., Luo M., Qiu S., Chattopadhyay D., Fan X., Torrence P.F., Kern E.R. Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob. Agents Chemother. 2007, 51:1795-1803.
90. Prichard M.N., Williams A.D., Keith K.A., Harden E.A., Kern E.R. Distinct thymidine kinases encoded by cowpox virus and herpes simplex virus contribute significantly to the differential antiviral activity of nucleoside analogs. Antiviral Res. 2006, 71:1-6.
91. Ratia K., Pegan S., Takayama J., Sleeman K., Coughlin M., Baliji S., Chaudhuri R., Fu W., Prabhakar B.S., Johnson M.E., Baker S.C., Ghosh A.K., Mesecar A.D. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. USA 2008, 105:16119-16124.
92. Reinders Folmer S.C., Danner S.A., Bakker A.J., Lange J.M., van Steenwijk R.P., Alberts C., van Keulen P.H., van der Schoot J.B. Gallium-67 lung scintigraphy in patients with acquired immune deficiency syndrome (AIDS). Eur. J. Respir. Dis. 1986, 68:313-318.
93. Rudin M., Rausch M., Stoeckli M. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods. Mol. Imaging Biol. 2005, 7:5-13.
94. Saito Y., Rubenstein R., Price R.W., Fox J.J., Watanabe K.A. Diagnostic imaging of herpes simplex virus encephalitis using a radiolabeled antiviral drug: autoradiographic assessment in an animal model. Ann. Neurol. 1984, 15:548-558.
95. Serganova I., Ponomarev V., Blasberg R. Human reporter genes: potential use in clinical studies. Nucl. Med. Biol. 2007, 34:791-807.
96. Shields A.F. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol. Imaging Biol. 2006, 8:141-150.
97. Sluis-Cremer N., Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 2008, 134:147-156.
98. Stumpf W.E. Drug localization and targeting with receptor microscopic autoradiography. J. Pharmacol. Toxicol. Methods 2005, 51:25-40.
99. Victor F., Brown T.J., Campanale K., Heinz B.A., Shipley L.A., Su K.S., Tang J., Vance L.M., Spitzer W.A. Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime. J. Med. Chem. 1997, 40:1511-1518.
100. Welin M., Kosinska U., Mikkelsen N.E., Carnrot C., Zhu C., Wang L., Eriksson S., Munch-Petersen B., Eklund H. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc. Natl. Acad. Sci. USA 2004, 101:17970-17975.
101. Woodward G.E., Hudson M.T. The effect of 2-desoxy-D-glucose on glycolysis and respiration of tumor and normal tissues. Cancer Res. 1954, 14:599-605.
102. Wu H., Pfarr D.S., Johnson S., Brewah Y.A., Woods R.M., Patel N.K., White W.I., Young J.F., Kiener P.A. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 2007, 368:652-665.
103. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol. 2005, 79:13139-13149.
104. Yarchoan R., Berg G., Brouwers P., Fischl M.A., Spitzer A.R., Wichman A., Grafman J., Thomas R.V., Safai B., Brunetti A., et al. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet 1987, 1:132-135.